Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Chemistry

• Publication date

  2008-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1373/clinchem.2007.099747PMID 18436719
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study].

  2010cited by this paper
• Proprotein convertase subtilisin kexin type 9 (PCSK9)

  2010cited by this paper
• Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.

  2008cited by this paper
• The PPARα-Humanized Mouse: A Model to Investigate Species Differences in Liver Toxicity Mediated by PPARα

  2008cited by this paper
• The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha.

  2008cited by this paper
• Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 Published, JLR Papers in Press, November 21, 2007.

  2008cited by this paper
• Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse.

  2007cited by this paper
• Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice Published, JLR Papers in Press, January 22, 2007.

  2007cited by this paper
• Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation*

  2007cited by this paper
• Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis Published, JLR Papers in Press, April 20, 2007.

  2007cited by this paper
• The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR

  2007cited by this paper
• The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.

  2007cited by this paper
• Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.

  2007influential reference
• Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity.

  2007cited by this paper
• Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?

  2007cited by this paper
• Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly

  2007cited by this paper
• Unravelling the functional significance of PCSK9

  2007influential reference
• Effects of pH and Low Density Lipoprotein (LDL) on PCSK9-dependent LDL Receptor Regulation*

  2007cited by this paper
• Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

  2007cited by this paper
• Plasma PCSK9 levels correlate with cholesterol in men but not in women.

  2007influential reference
• Catalytic Activity Is Not Required for Secreted PCSK9 to Reduce Low Density Lipoprotein Receptors in HepG2 Cells*

  2007cited by this paper
• Molecular biology of PCSK9: its role in LDL metabolism.

  2007cited by this paper
• Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.

  2006influential reference
• Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c*

  2006cited by this paper
• Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

  2006influential reference
• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  2005cited by this paper
• Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

  2005influential reference
• Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia

  2004cited by this paper
• Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver*

  2004cited by this paper
• PPARs and the complex journey to obesity

  2004cited by this paper

• Relationship between lipoprotein(a) and PCSK9 in angiogram-proven premature coronary artery disease in an Asian cohort

  2026cites this paper
• Impact of conventional lipid-lowering therapy on circulating levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis of randomised controlled trials.

  2026cites this paper
• Association of Plasma PCSK9 with Hypercholesterolemia in Patients with Nephrotic Syndrome

  2025cites this paper
• The pleiotropic effects of PCSK9 in cardiovascular diseases beyond cholesterol metabolism

  2025cites this paper
• Effects of Pemafibrate on Cholesterol Synthesis and Absorption: a Post-Hoc Subgroup Analysis of a Phase 2 Clinical Trial

  2025cites this paper
• PCSK9 in metabolism and diseases.

  2024cites this paper
• Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside

  2024cites this paper
• A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022

  2023cites this paper
• Adverse outcome pathway for pregnane X receptor-induced hypercholesterolemia

  2023cites this paper
• Therapeutic Application of Berberine: a Consolidated Review

  2023cites this paper
• Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren

  2022cites this paper
• Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond

  2022cites this paper
• Acanthaster planci Inhibits PCSK9 Gene Expression via Peroxisome Proliferator Response Element (PPRE) and Activation of MEK and PKC Signaling Pathways in Human Liver Cells

  2022cites this paper
• The R93C Variant of PCSK9 Reduces the Risk of Premature MI in a Chinese Han Population

  2022cites this paper
• The Multifaceted Biology of PCSK9

  2021cites this paper
• Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes

  2021cites this paper
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis

  2021cites this paper
• Acaudina molpadioides mediates lipid uptake by suppressing PCSK9 transcription and increasing LDL receptor in human liver cells

  2021cites this paper
• Combined intake of glucose-and lipid-lowering medications further elevates plasma levels of PCSK9 in type 2 diabetes patients.

  2020cites this paper
• Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy

  2020cites this paper
• Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall

  2020cites this paper
• Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients

  2020cites this paper
• The role of the C-terminal domain of PCSK9 and SEC24 isoforms in PCSK9 secretion.

  2020cites this paper
• Efficacy of Nutraceutical Combination of Monacolin K, Berberine, and Silymarin on Lipid Profile and PCSK9 Plasma Level in a Cohort of Hypercholesterolemic Patients

  2020cites this paper
• Immunogenetics of Atherosclerosis—Link between Lipids, Immunity, and Genes

  2020cites this paper
• The marine‐derived furanone reduces intracellular lipid accumulation in vitro by targeting LXRα and PPARα

  2020cites this paper
• Circulating PCSK9 concentrations are increased in postmenopausal women with the metabolic syndrome.

  2019cites this paper
• Ginkgolide B Mediated Alleviation of Inflammatory Cascades and Altered Lipid Metabolism in HUVECs via Targeting PCSK-9 Expression and Functionality

  2019cites this paper
• The Regulation of PCSK9 Structure and Function Through Lipoprotein Interactions

  2019cites this paper
• Indirect regulation of PCSK9 gene in inflammatory response by Porphyromonas gingivalis infection

  2019cites this paper
• PCSK9 is Expressed in Human Visceral Adipose Tissue and Regulated by Insulin and Cardiac Natriuretic Peptides

  2019cites this paper
• Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents

  2019cites this paper
• Genotyping and Frequency of PCSK9 Variations Among Hypercholesterolemic and Diabetic Subjects

  2018cites this paper
• Berberrubine and its analog, hydroxypropyl‐berberrubine, regulate LDLR and PCSK9 expression via the ERK signal pathway to exert cholesterol‐lowering effects in human hepatoma HepG2 cells

  2018cites this paper
• Up-regulation of PCSK9 gene expression and diminished level of LDL-receptor in rat liver as a potential cause of post-lipectomy hypercholesterolemia

  2018cites this paper
• Is hepatic peroxisome proliferator‐activated receptor α essential for the metabolic effects of fibrates?

  2018cites this paper
• Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?

  2018cites this paper
• Role of PCSK9 in lipid metabolism and atherosclerosis.

  2018cites this paper
• Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting

  2018cites this paper
• Circulating PCSK9 is lowered acutely following surgery

  2018cites this paper
• Update on the Benefits and Mechanisms of Action of the Bioactive Vegetal Alkaloid Berberine on Lipid Metabolism and Homeostasis

  2018cites this paper
• siRNA-mediated inhibition of SREBP cleavage-activating protein reduces dyslipidemia in spontaneously dysmetabolic rhesus monkeys.

  2017cites this paper
• Predicting proprotein convertase subtilisin kexin type-9 loss of function mutations using plasma PCSK9 concentration.

  2017cites this paper
• Implications of GLAGOV study

  2017cites this paper
• LESSONS FROM ARTERIAL WALL IMAGING TRIALS OF LIPID LOWERING

  2017cites this paper
• Circulating PCSK9 affects serum LDL and cholesterol levels more than SREBP-2 expression.

  2017cites this paper
• Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice

  2017cites this paper
• PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies

  2017cites this paper
• Hypercholesterolemia: The role of PCSK9.

  2017cites this paper
• Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters.

  2017cites this paper
• PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade

  2017cites this paper
• PCSK9 Inhibitors: Treating the Right Patients in Daily Practice

  2017cites this paper
• Lipid Lowering Therapy and Circulating PCSK9 Concentration

  2017cites this paper
• Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD?

  2017cites this paper
• Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima–media thickness in hypertensives

  2016cites this paper
• Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese

  2016cites this paper
• Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.

  2016cites this paper
• PCSK9 as a Biomarker of Cardiovascular Disease

  2016cites this paper
• Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.

  2016cites this paper
• Independent Link Between Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and FABP4 in a General Population Without Medication.

  2016cites this paper
• Xanthohumol improves dysfunctional glucose and lipid metabolism in diet-induced obese C57BL/6J mice.

  2016cites this paper
• Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)

  2016cites this paper
• Determination of cholesterol in blood. Part 3

  2016cites this paper
• [Proprotein Convertase Subtilisin/Kexin-Type 9 (PCSK9) New Opportunities of Lipid-Lowering Therapy].

  2016cites this paper
• Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes

  2016cites this paper
• The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy

  2016cites this paper
• A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts.

  2015cites this paper
• PCSK9 and triglyceride-rich lipoprotein metabolism

  2015cites this paper
• Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia.

  2015cites this paper
• Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.

  2015cites this paper
• PCSK9: The functional relevance of fenofibrate–statin combination therapy to reduce residual cardiovascular risk

  2015cites this paper
• Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9

  2015cites this paper
• Decreased PCSK9 expression in human hepatocellular carcinoma

  2015cites this paper
• Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)

  2015cites this paper
• Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9.

  2015cites this paper
• Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention

  2015cites this paper
• Response to letter regarding article, "Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms".

  2015cites this paper
• The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance.

  2015cites this paper
• High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels.

  2015cites this paper
• PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.

  2015cites this paper
• Genetic and metabolic studies of APOE, PCSK9, TM6SF2 and PNPLA3

  2014cites this paper
• PCSK9: A Key Modulator of Cardiovascular Health

  2014cites this paper
• LDL cholesterol PCSK 9 A Key Modulator of Cardiovascular Health

  2014cites this paper
• PCSK9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein-B Lipoproteins Through Both LDL-Receptor Dependent and Independent Mechanisms Running title: Rashid et al.; PCSK9 Promotes Intestinal ApoB Overproduction

  2014cites this paper
• PCSK9 and lipid lowering drugs.

  2014cites this paper
• Isolation and characterization of the circulating truncated form of PCSK9[S]

  2014cites this paper
• Genetic and metabolic studies of APOE , PCSK 9 TM 6 SF 2 and PNPLA 3

  2014cites this paper
• PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges.

  2014cites this paper
• Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction

  2014cites this paper
• Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.

  2014cites this paper
• Circulating Levels of Proprotein Convertase Subtilisin Kexin Type 9 are Elevated by Fibrate Therapy: A Systematic Review and Meta-Analysis of Clinical Trials

  2014cites this paper
• Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs

  2014cites this paper
• Inhibition of PCSK9 Transcription by Berberine Involves Down-regulation of Hepatic HNF1α Protein Expression through the Ubiquitin-Proteasome Degradation Pathway*

  2014cites this paper
• Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.

  2014cites this paper
• Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms

  2014cites this paper
• 0447: Elevated plasma PCSK9 is equally detrimental for non-familial hypercholesterolemic (non-FH) and heterozygous FH patients, irrespective of their LDL receptor defects

  2014cites this paper
• Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels.

  2014cites this paper
• Targeting PCSK9 for hypercholesterolemia.

  2014cites this paper
• Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes

  2014cites this paper
• Perspektiven zu cholesterinwirksamer Behandlung 2014

  2014cites this paper